AGTC and The University of Massachusetts Medical School Report Promising Phase II Gene Therapy Clinical Data

18-11-2013 Business Wire HealthComments (0)


AGTC, a clinical stage biotechnology company today reported encouraging results from a phase II clinical trial using the Company’s proprietary AAV gene therapy vector system.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top